SPD 756

Drug Profile

SPD 756

Alternative Names: BCH 13520

Latest Information Update: 19 Mar 2010

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire
  • Class Antivirals; Purines; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 22 Mar 2004 SPD 756 is available for partnering (http://www.shire.com)
  • 15 Nov 2002 A preclinical study has been added to the Viral Infections pharmacodynamics section
  • 24 Sep 2002 A phase I study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top